In silico analysis on inhibitory potentials of derived peptides from human breast milk against SARS-CoV-2 infection

Clicks: 4
ID: 285043
2021
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #513 of 3,757 articles by views in Malay Journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 3,757 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Novel therapeutic drug discovery against the severe acute respiratory syndrome-corona virus-2 (SARS-CoV-2) focuses on in silico analysis of potential medicines that inhibit the viral entry, proteases, and replication. Human breast milk contains compounds, bioactive peptides, essential for the growth, nutrition, and protection of children. In the present study, six known bioactive peptides derived from human breast milk were analyzed in silico for their potential inhibitory activity on angiotensin-converting enzyme 2 (ACE2), dipeptidyl peptidase 4 (DPP4), and SARS-CoV-2 spike protein. These peptides were found to have significant inhibitory activity and are non-toxic. The active amino acids within these peptides that interact with ACE2 and DPP4 were also identified. Molecular docking shows that all six peptides may exhibit non-competitive inhibition in which it binds to other sites of the protein which may induce conformational changes and prevent viral attachment. The docking scores revealed that the binding affinities of these peptides to ACE2, DPP4, and SARS-CoV-2 spike protein are stronger than SARS-CoV-2 spike protein to ACE2 and DPP4. Among these six peptides, IYPSFQPQPLI is found to be the best inhibitor for ACE2, DPP4, and SARS-CoV-2 spike protein. These peptides are potential drug candidates for coronavirus disease-2019 (COVID-19) treatment, however, in vitro and in vivo studies must be conducted to ensure efficacy and safety.
Reference Key
persistent_1760654457_68f17479c4ab1 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Villapaz, Rogel L
Journal Malay Journal
Year 2021
DOI
DOI not found
URL
https://animorepository.dlsu.edu.ph/etdb_chem/2
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.